Drugs / cRGDY-PEG-Cy5.5-C dots
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02106598 | Apr 2014 → Apr 2027 expected | melanoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cRGDY-PEG-Cy5.5-C dots | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106598 ↗ |
| Known as | Cornell prime dots | “OBJECTIVE: To evaluate whether an ultrasmall, molecularly targeted core-shell silica nanoparticle (Cornell prime dots) can safely and reliably identify optically avid SLNs in...” PMID 33734415 ↗ Mar 2021 |
| Modality | Diagnostic / imaging agent | “fluorescence-guided SLN biopsy” PMID 33734415 ↗ Mar 2021 |